Price (delayed)
$23.74
Market cap
$1.36B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.34
Enterprise value
$1.19B
We are a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Our differentiated
There are no recent dividends present for GPCR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.